CATX · AMEX
Perspective Therapeutics (CATX) Stock Price & Fundamentals
Perspective Therapeutics (CATX) closed at $304.03 on Oct 9, 2026, down 0.32% from the previous close of $305.00.
Share price, past year
1Y +18.74%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $304.03 |
| Sep 30, 2026 | $299.36 |
| Aug 31, 2026 | $305.56 |
| Jul 31, 2026 | $299.19 |
| Jun 30, 2026 | $292.47 |
| May 29, 2026 | $303.70 |
| Apr 30, 2026 | $312.71 |
| Mar 31, 2026 | $304.17 |
| Feb 27, 2026 | $288.34 |
| Jan 30, 2026 | $290.93 |
| Dec 31, 2025 | $273.12 |
| Nov 28, 2025 | $273.56 |
| Oct 31, 2025 | $256.79 |
Key statistics
- Market cap
- $34.69B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.33
- Revenue (TTM)
- —
- Net income (TTM)
- −$116.43M
- Shares outstanding
- 114.1M
- Dividend yield
- —
- 52-week range
- $252.66 – $312.71
Perspective Therapeutics's market cap is $34.69B, based on a share price of $304.03 and 114.1M shares outstanding as of Jun 30, 2026.
Financials
Perspective Therapeutics reported revenue of $1.43M for fiscal 2023, down 86.72% from fiscal 2022.
Perspective Therapeutics reported a net loss of $103.12M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $1.43M | −86.7% | −$46.51M | −3,243.2% | −$1.74 | −$37.99M |
| FY2022ended Jun 30, 2022 | $10.80M | +7.4% | −$7.27M | −67.4% | — | −$7.98M |
| FY2021ended Jun 30, 2021 | $10.05M | +3.9% | −$3.39M | −33.7% | −$0.30 | −$3.22M |
| FY2020ended Jun 30, 2020 | $9.68M | +32.4% | −$3.45M | −35.6% | −$0.50 | −$3.91M |
| FY2019ended Jun 30, 2019 | $7.31M | +23.5% | −$5.14M | −70.3% | −$0.80 | −$5.49M |
| FY2018ended Jun 30, 2018 | $5.92M | +24.4% | −$6.70M | −113.1% | −$1.20 | −$6.05M |
| FY2017ended Jun 30, 2017 | $4.76M | −0.2% | −$6.16M | −129.4% | −$1.10 | −$6.26M |
| FY2016ended Jun 30, 2016 | $4.77M | +3.5% | −$4.71M | −98.8% | −$0.90 | −$4.36M |
| FY2015ended Jun 30, 2015 | $4.61M | +9.2% | — | — | −$0.70 | — |
| FY2014ended Jun 30, 2014 | $4.22M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2023ended Sep 30, 2023 | $2.19M | — | — |
| Q2 FY2023ended Jun 30, 2023 | $2.09M | — | — |
| Q1 FY2023ended Mar 31, 2023 | $2.06M | — | — |
| Q4 FY2022ended Jun 30, 2022 | $2.51M | — | — |
| Q3 FY2022ended Mar 31, 2022 | $2.91M | — | — |
| Q2 FY2022ended Dec 31, 2021 | $2.82M | — | — |
| Q1 FY2022ended Sep 30, 2021 | $2.56M | — | — |
| Q4 FY2021ended Jun 30, 2021 | $2.71M | — | — |
Company profile
- Name
- Perspective Therapeutics, Inc.
- Ticker
- CATX
- Exchange
- AMEX
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2401 Elliott Avenue, Suite 320, Seattle, WA 98121
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000728387
Recent SEC filings
- Oct 8, 2026
- Oct 1, 2026
- Sep 14, 2026
- Sep 8, 2026
- Aug 10, 2026
- Aug 10, 2026
- Aug 3, 2026
- Jul 1, 2026
Frequently asked questions
What is Perspective Therapeutics's stock price?
Perspective Therapeutics (CATX) closed at $304.03 on Oct 9, 2026, down 0.32% from the previous close of $305.00.
What is Perspective Therapeutics's market cap?
Perspective Therapeutics's market cap is $34.69B, based on a share price of $304.03 and 114.1M shares outstanding as of Jun 30, 2026.
How much revenue does Perspective Therapeutics make?
Perspective Therapeutics reported revenue of $1.43M for fiscal 2023, down 86.72% from fiscal 2022.
Does Perspective Therapeutics pay a dividend?
Perspective Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Perspective Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures